NGL Fine Chem Ltd Stock Price Today (NSE: NGLFINE)
Fundamental Score
NGL Fine Chem Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
NGL Fine Chem Ltd share price today is ₹3260.30, down 0.60% on NSE/BSE as of 31 July 2026. NGL Fine Chem Ltd (NGLFINE) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.96K (Cr). The 52-week high for NGLFINE share price is ₹3349.00 and the 52-week low is ₹1175.50. At a P/E ratio of 47.04x, NGLFINE is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 13.89% and a debt-to-equity ratio of 0.34.
NGL Fine Chem Ltd Share Price Chart — NSE/BSE Historical Performance
NGL Fine Chem Ltd share price chart: 8.58% return over the past month. 52-week high ₹3349.00, 52-week low ₹1175.50.
NGL Fine Chem Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹3330.10 | ₹3333.60 | ₹3250.00 | ₹3260.30 | 2.44K (Cr) | |
| ₹3278.00 | ₹3299.20 | ₹3229.00 | ₹3280.00 | 3.67K (Cr) | |
| ₹3212.40 | ₹3255.50 | ₹3100.00 | ₹3251.50 | 7.17K (Cr) | |
| ₹3220.50 | ₹3238.30 | ₹3087.20 | ₹3212.00 | 6.38K (Cr) | |
| ₹3210.00 | ₹3349.00 | ₹3177.50 | ₹3226.50 | 7.53K (Cr) | |
| ₹3141.60 | ₹3218.90 | ₹3132.20 | ₹3205.50 | 2.15K (Cr) | |
| ₹3010.00 | ₹3289.90 | ₹2995.30 | ₹3237.40 | 16.80K (Cr) | |
| ₹3150.00 | ₹3176.40 | ₹2953.70 | ₹3010.00 | 9.33K (Cr) | |
| ₹3090.10 | ₹3179.80 | ₹3054.10 | ₹3131.90 | 5.13K (Cr) | |
| ₹3138.10 | ₹3159.00 | ₹3063.00 | ₹3087.40 | 2.98K (Cr) |
NGL Fine Chem Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹3062.00 | ₹3349.00 | ₹2900.00 | ₹3260.30 | +6.48% | |
| ₹2834.40 | ₹3232.00 | ₹2550.00 | ₹3107.50 | +9.64% | |
| ₹2202.00 | ₹3005.00 | ₹2106.10 | ₹2785.10 | +26.48% | |
| ₹2100.00 | ₹2495.00 | ₹2021.30 | ₹2214.50 | +5.45% | |
| ₹2232.00 | ₹2575.00 | ₹1998.10 | ₹2057.10 | -7.84% | |
| ₹1730.00 | ₹2575.00 | ₹1659.20 | ₹2301.20 | +33.02% | |
| ₹1413.20 | ₹1800.00 | ₹1357.00 | ₹1677.30 | +18.69% | |
| ₹1325.20 | ₹1433.90 | ₹1271.00 | ₹1406.20 | +6.11% | |
| ₹1511.60 | ₹1650.00 | ₹1294.70 | ₹1340.90 | -11.29% | |
| ₹1419.30 | ₹1563.80 | ₹1410.00 | ₹1504.30 | +5.99% | |
| ₹1432.00 | ₹1564.90 | ₹1331.70 | ₹1405.40 | -1.86% | |
| ₹1345.90 | ₹1499.00 | ₹1175.50 | ₹1422.70 | +5.71% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Overvalued animal health API player needs flawless execution to justify its premium valuation; otherwise, it's a short.
WHAT'S HAPPENING NOW (last 2-4 weeks)
NGL Fine Chem's stock demonstrated mixed momentum, closing at on April 2, 2026, a 1.17% weekly gain, outperforming the Sensex which declined by 0.29%. MarketsMOJO downgraded NGL Fine Chem from Buy to Hold on April 1, 2026, citing mixed technical and valuation signals despite strong recent earnings. NGL Fine-Chem submitted its mandatory SEBI compliance certificate for Q4FY26 on April 6, 2026.
CORE STORY (THE REAL GAME)
NGL Fine Chem is trying to transition from a pure-play animal health API manufacturer to a regulated markets player with backward integration. The market is watching if they can execute the capex and regulatory approvals to justify the premium valuation.
- Q3 FY26 earnings surge driven by strong demand
- Progress on ₹160 crore greenfield expansion at Tarapur
- Downgrade to Hold signals caution amid mixed signals
- Successful diversification into regulated markets
- Timely completion of the ongoing capital projects
- Positive regulatory audits
- Small-cap: Liquidity risk
- High P/E: Valuation appears stretched
- Executional delays in CAPEX
No major change in FII/DII/Promoter holdings.
Indian pharma exports are growing, projected to reach $130 billion by 2030, but faces global pricing pressures.
NGL Fine Chem has invested ₹119.83 crore in Q1 for the expansion of its S-18 plant. CAPEX completion is now expected in Q4 due to executional delays.
No: Free Cash Flow 5Y: ₹-45.98 Cr.
Focus on completing the Tarapur expansion and obtaining regulatory approvals. Expect commercial production to begin in the second half of FY28.
Primary Thesis Risk
Failure to diversify into regulated markets will lead to de-rating.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
NGL Fine Chem Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
NGL Fine Chem Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NGLFINE across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Excellent ROCE Performance (15.07%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Robust Profit Growth (2282.69%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (55.61%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (13.62% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Interest Coverage (13.41x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (72.74%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Premium Valuation Risk (P/E: 47.04x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-5.58% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-5.58% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-121.98 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.03%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
NGL Fine Chem Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare NGL Fine Chem Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
NGL Fine Chem LtdNGL Fine Chem L...Selected✓ NGLFINE • 524774 | 49.3/100 | ₹3260.30₹3260 | ₹1958.21₹1958.21 | 47.04Average 47.0 Average | 13.89%Average 13.89% Average | 15.07%Good 15.07% Good | 0.34Excellent 0.3 Excellent | -5.58%Poor -5.58% Poor | 13.62%Good 13.62% Good | 0.06% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
NGL Fine Chem Ltd PE Ratio History
Historical price-to-earnings ratio for NGLFINE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹34.19 | ₹1406.20 | 41.1x |
| FY 2024 | ₹66.88 | ₹1811.15 | 27.1x |
| FY 2023 | ₹33.18 | ₹2230.45 | 67.2x |
| FY 2022 | ₹80.77 | ₹1536.10 | 19x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
NGL Fine Chem Ltd Dividend History
Annual cash dividends paid by NGLFINE — dividend yield 0.06%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1.08 Cr |
| FY 2024 | ₹1.08 Cr |
| FY 2023 | ₹1.08 Cr |
| FY 2022 | ₹1.08 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
NGL Fine Chem Ltd Quarterly Performance
Latest quarterly metrics for NGLFINE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
55.61%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
2282.69%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.62%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-5.58%
Compounded annual net profit growth over 5 years
NGL Fine Chem Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for NGLFINE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
NGL Fine Chem Ltd Financial Statements
Annual income statement, balance sheet and cash flow for NGL Fine Chem Ltd (NGLFINE) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for NGL Fine Chem Ltd
About NGLFINE (NGL Fine Chem Ltd)
NGL Fine Chem Ltd is a dynamic player in the pharmaceutical landscape, specializing in the development and manufacturing of high-quality active pharmaceutical ingredients (APIs) an...d advanced intermediates. With a strong emphasis on innovation, NGLFINE caters to both the veterinary and human health sectors, serving as a reliable partner for pharmaceutical companies worldwide. The company's commitment to rigorous quality standards and cutting-edge technology ensures the consistent production of safe and effective products, contributing to improved health outcomes for both animals and humans. NGLFINE operates with a global perspective, serving clients across diverse markets through strategic partnerships and a robust supply chain network. NGLFINE distinguishes itself through a comprehensive portfolio of specialized APIs tailored to address critical health needs. In the veterinary arena, NGLFINE offers a range of antiparasitic and therapeutic compounds designed to combat common animal ailments, enhancing livestock health and productivity. For human health applications, NGLFINE provides crucial ingredients for a variety of pharmaceutical formulations, focusing on areas where unmet needs exist. The company's focus extends beyond manufacturing, as it actively invests in research and development to expand its product offerings and explore novel therapeutic solutions. This dedication to innovation positions NGLFINE at the forefront of the pharmaceutical industry, driving advancements in healthcare. NGLFINE is deeply committed to environmental sustainability and ethical business practices. The company operates with a responsible approach, implementing measures to minimize environmental impact throughout its manufacturing processes. By adhering to stringent regulatory guidelines and prioritizing workplace safety, NGLFINE fosters a culture of integrity and accountability. This commitment extends to its relationships with customers, suppliers, and the communities in which it operates, fostering trust and long-term partnerships. NGLFINE's dedication to quality, innovation, and sustainability underscores its mission to improve global health while operating responsibly.
Company Details
Key Leadership
Corporate Events
NGLFINE Share Price: Frequently Asked Questions
What is the current share price of NGL Fine Chem Ltd?
NGL Fine Chem Ltd (NGLFINE) trades at ₹3260.30 on NSE and BSE. Market cap ₹1.96K (Cr). Educational data only.
What is the P/E ratio of NGL Fine Chem Ltd?
NGL Fine Chem Ltd has a P/E of 47.04x vs industry average 34.89x.
What is the Bull Run score for NGL Fine Chem Ltd?
NGL Fine Chem Ltd has a Bull Run score of 49.3/100 based on 25+ financial parameters.
Does NGL Fine Chem Ltd pay dividends?
NGL Fine Chem Ltd has a dividend yield of 0.06%. Past dividends don't guarantee future payments.
What is the ROE of NGL Fine Chem Ltd?
NGL Fine Chem Ltd has ROE of 13.89%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of NGL Fine Chem Ltd?
NGL Fine Chem Ltd has debt-to-equity of 0.34.
Is NGL Fine Chem Ltd a good investment?
Bull Run gives NGL Fine Chem Ltd a score of 49.3/100. This is not investment advice — consult a SEBI-registered advisor.